GEMLIEVA 1000MG ( Gemcitabine for Injection IP 1000mg )

GEMLIEVA 1000 mg contains Gemcitabine, a pyrimidine nucleoside analogue antimetabolite chemotherapy drug. After intracellular activation, it inhibits DNA synthesis and triggers apoptosis in rapidly dividing cancer cells.

Gemcitabine is indicated for the treatment of:

1. Pancreatic Cancer

2. Non-Small Cell Lung Cancer (NSCLC)
    – Alone or in combination with cisplatin

3. Breast Cancer
    – Metastatic disease

4. Ovarian Cancer
    – Platinum-resistant or recurrent disease

5. Bladder Cancer

Common side effects:

•  Myelosuppression (neutropenia, thrombocytopenia, anemia)

•  Nausea, vomiting

•  Fatigue

•  Fever, flu-like symptoms

Other side effects:

•  Elevated liver enzymes

•  Skin rash

Serious side effects:

•  Pulmonary toxicity (rare)

•  Hemolytic uremic syndrome (very rare)

 Regular monitoring of CBC, liver, and renal function is essential.

Dosage is calculated based on body surface area (BSA) and treatment protocol.

Common regimens:

•  1000–1250 mg/m² IV

•  Administered on Days 1, 8, and 15 of a 28-day cycle
    or Days 1 and 8 of a 21-day cycle

1000 mg vials are commonly used for full-dose administration.

NOTE: This medicine should be taken only under a doctor’s supervision.